Fig. 1 · Structure

Documents & Downloads

Ticlopidine HCl

Cat. No. A11690 CAS 53885-35-1
Ticlopidine is an adenosine diphosphate (ADP) receptor inhibitor. It inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
Platelet IC50 0.36 mM Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins prior to ADP-challenge measured within 5 mins by Born's turbidimetric analysis [PMID: 23509954]

Ticlopidine HCl Research Summary

This section summarizes 2 in vitro studies of Ticlopidine HCl from 2 published references. In vitro models include CYP2C19.

Ticlopidine HCl In Vitro Studies

Ticlopidine at varying concentrations did not suppress constitutive hGPR17 isoform activity in transiently transfected HEK293 cells, as assessed by CREB activity. In CYP2C19 assays, Ticlopidine HCl at 5 μM induced a statistically significant decrease in metabolite formation, with a reported IC50 of 4.3 μM for inhibition of S-mephenytoin hydroxylation. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Ticlopidine effects on constitutive hGPR17 activity

Cell-based study · HEK293 cells transiently transfected with Gqi4myr, CREB-Luc reporter plasmid and receptor or pcDNA3; hGPR17 isoforms [1]

HEK293 cells transiently transfected with hGPR17 isoforms and a CREB-Luc reporter were incubated with varying concentrations of Ticlopidine. Ticlopidine did not suppress the constitutive activity of any hGPR17 isoform.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CREB activityReported result Ticlopidine did not suppress the constitutive activity of any of the hGPR17 isoforms[1]

Literature-Reported Treatment Conditions

Treatment concentration
varying concentrations
Exposure duration
24 h before substrate addition
Method
incubated with the ligand
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Ticlopidine

The paper names Ticlopidine without stating the salt or form; not verified as the hydrochloride form supplied as A11690. No dose conversion or lot validation.

Methods > cAMP response element binding protein trans-reporter luciferase assay (S44, S47); Results > The uracil nucleotides UDP-glucose, UDP-galactose and UDP activate hGPR17-S and -L with different potencies (S154); Figure 6 legend (S255, S256, S257, S258)

CREB activity: CREB activity; comparator: activity in absence of the ligand — Methods > cAMP response element binding protein trans-reporter luciferase assay (S44); Results > The uracil nucleotides UDP-glucose, UDP-galactose and UDP activate hGPR17-S and -L with different potencies (S154)

Ticlopidine inhibition of CYP2C19 activity

Cell-based study · CYP2C19 [2]

In CYP2C19 assays, Ticlopidine HCl at 5 μM induced a statistically significant decrease in metabolite formation compared with solvent controls. The reported IC50 for inhibition of CYP2C19-catalyzed S-mephenytoin hydroxylation was 4.3 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CYP2C19-catalyzed S-mephenytoin hydroxylationIC50 substrate concentrations: 5 µM in each assay; IC50 = 4.3 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Vehicle
DMSO did not exceed 0.6 v/v%
Reported limits
Not stated in the sentences used: route, schedule.
Methods and source locations

Compound reported in the paper: Ticlopidine HCl; Compound label in the paper: Ticlopidine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. CYP Assays (S7, S8); Figure 2 legend (S94, S95)

CYP2C19-catalyzed S-mephenytoin hydroxylation: CYP2C19-catalyzed S-mephenytoin hydroxylation; comparator: solvent controls — Figure 2 legend (S94, S95)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 53885-35-1
Formula C14H14ClNS.HCl
Molecular Weight 300.25
SMILES
C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 1 mg/mL (3.33 mM)
Water 3 mg/mL (9.99 mM)
Ethanol 1 mg/mL (3.33 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ticlopidine HCl Research References

  1. [1] Benned-Jensen T, Rosenkilde MM. Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants. Br J Pharmacol (2010). PMID: 20148890 DOI: 10.1111/j.1476-5381.2009.00633.x Source material
  2. [2] Mohos V, Fliszár-Nyúl E, Ungvári O, et al. Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters. Nutrients (2020). PMID: 32751996 DOI: 10.3390/nu12082306 Source material

Added to your cart

View Cart Checkout
Loading...